Top ten ‘office relics' from fax machines to floppy disks, survey finds
A poll, of 2,000 employed adults, found many were more than happy to wave goodbye to landline desk phones, business card holders and even floppy disks.
2
2
While others said good riddance to correction fluid, hole punches and paper diaries or planners, which once ruled their desks.
Now 52 per cent treat their smartphone as a fully-fledged portable office, with 62 per cent claiming it has improved their ability to multitask at work.
Annika Bizon, from Samsung, which commissioned the research to mark the launch of the AI business enhanced Galaxy Z Fold7 Enterprise Edition, that aims to give workers the ability to work the way they want, said: 'Thanks to cutting-edge technology, the modern office looks nothing like it did 25 years ago.
'Today's professionals don't work in one place or on one schedule, and their tech shouldn't be confined to any restraints either.'
It also emerged 50 per cent of workers begin their workday on the commute at least some, if not all, the days they travel in to work.
And when they're in the office, this has also undergone modernisation - now featuring comfortable seating areas (41 per cent), relaxation spaces (39 per cent) and collaboration pods (23 per cent).
Throughout the working week, 37 per cent now have fully office-based jobs.
With just under one in five (18 per cent) splitting their time 50/50 between the office and home.
A further 21 per cent mainly work remotely now.
As such, just 37 per cent have assigned seats or desk space at work, with over a quarter (26 per cent) hotdesking instead.
Samsung's latest AI fridge is full of mega tricks
With more digital technology being used in the workplace, 61 per cent have received employee training when it comes to using evolving software.
However, 12 per cent of those aged 50 and over admitted to struggling to incorporate software into their working lives.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
7 minutes ago
- Reuters
South Korea trade envoy says Samsung, SK Hynix will not be subject to 100% US tariffs on chips
SEOUL, Aug 7 (Reuters) - South Korea's top trade envoy Yeo Han-koo said on Thursday that chipmakers Samsung Electronics ( opens new tab and SK Hynix ( opens new tab will not be subject to 100% U.S. tariffs on chips. Yeo said on radio that among various countries South Korea will face the most favourable U.S. tariff rates on chips under the trade deal between Washington and Seoul.
The Sun
37 minutes ago
- The Sun
15 reasons why the Ford Transit is the GOAT of the van world – from transporting rock bands, elephants and even ROYALS
WE could argue all night about who is the GOAT. 15 15 15 But when it comes to vehicles, it's not even a debate. G reatest O f A ll T ransit. The humble Ford Transit has been Britain's best-selling van since day one - August 9, 1965. That's like Liverpool winning the Prem for 60 years on the bounce. Everyone else might as well give up and go home. To celebrate Transit's 60th, we've peppered today's column with quirky facts, as well as hearing from owners with a cherished van from each decade. Ford's famous Backbone Of Britain telly ad from the Eighties was genius marketing. Yet also 100 per cent true. Transit keeps this country ticking. Everything we see and touch was transported in a van. 15 15 One reason Transit is successful is that Ford engineers sit with owners to find ways of making the next model even more useful. Like the bloke who shoved a lump of wood through the bottom of the steering wheel to make a lunch table. The latest Transit Custom has a tilt-up steering wheel with a tray for his quinoa tuna salad. Bosh. Ford's insane V8 1971 Transit Supervan Retired builder Peter Lee, founder of the Transit Van Club, said: 'Transit is like a forklift with two doors. "Built to work. They're good honest vans that will do the job.' The OG and still the best. 3 MILLION UK sales and counting. Always available in white. 15 15 15 15 15 15
The Guardian
an hour ago
- The Guardian
Sales of Novo Nordisk's diabetes drugs including Ozempic slow sharply
Sales of Novo Nordisk's injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus. The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe's most valuable company, has lost nearly $100bn (£75bn) in market value since cutting its full-year sales forecast last week, when its share price slid 30% in its worst week in more than two decades. It fell a further 3% on Wednesday. On Wednesday, Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and appetite – grew by 8% in the first half of the year, down from 21% last year. Sales of obesity drugs including Wegovy increased by 56%, taking total sales 16% higher to 155bn Danish kroner (£18bn). Profit before tax climbed by 24% to 70.8bn kroner. The company has lost market share to its US rival Eli Lilly's Mounjaro, which studies have shown to be more effective, as well as cheaper versions made by generic drugmakers. It has also been hit by 'compounding' in the US, where pharmacies make up medications from ingredients, even though the US regulator declared an end to the practice recently. Novo Nordisk's outgoing chief executive, Lars Fruergaard Jørgensen, said that the copycat market had 'equal size to our business' and that compounded versions of Wegovy were sold at a 'much lower price point'. Its finance chief, Karsten Munk Knudsen, said the company was pursuing various strategies, including lawsuits against compounding pharmacies and expanding its US direct-to-consumer platform, NovoCare, launched in March. The company might also pursue 'cash sales' directly to patients elsewhere. Jørgensen said Novo Nordisk was taking measures to 'sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth'. He said it would probably not be able to avoid layoffs, but that no decision had been made. He said it would be up to Maziar Mike Doustdar, who takes over as CEO on Thursday, to make such a decision. The company is now expecting sales growth of between 8% and 14% at constant exchange rates in 2025, down sharply from its previous estimate of 13% to 21%. Novo Nordisk also disclosed that it had ditched several weight-loss drugs in development, including one that has just completed an intermediate (phase II) clinical study, 'due to portfolio considerations'. The company faces a class action lawsuit in the US from investors, who claim that it misled them with optimistic growth forecasts in the lucrative weight loss market. The UBS analyst Matthew Weston said: 'We expect GLP-1 compounders to remain in the US, which limits cash-pay uptake and leaves an uncertain outlook for US Wegovy. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion 'President Trump's proposal to reimburse GLP-1 obesity in Medicare could add significant volume uplift, but most-favoured-nation demands to offer US cash sales at European prices could significantly reduce value.' Derren Nathan, the head of equity research at Hargreaves Lansdown, said: 'Tariffs and drug pricing policy are another threat Mike Doustdar will need to tackle head-on if one of Denmark's greatest success stories is to regain its crown as Europe's most valuable company. 'The 15% blanket rate on EU imports is not necessarily the end of the story as Donald Trump dangles the prospect of levies of up to 250% on pharmaceutical imports under a separate section 232 investigation.'
